852508b0-5a5e-4730-8c70-6aabc0aa88be
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- age_years
- 81
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.480
- CHOLESTEROL_HOMEOSTASIS+0.430
- G2M_CHECKPOINT+0.410
- PROTEIN_SECRETION+0.390
- ANDROGEN_RESPONSE+0.360
- MITOTIC_SPINDLE+0.360
- MTORC1_SIGNALING+0.330
- UV_RESPONSE_DN+0.320
- GLYCOLYSIS+0.310
- HYPOXIA+0.300
Top 10 suppressed
- MYC_TARGETS_V2-0.470
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.180
- COAGULATION-0.140
- OXIDATIVE_PHOSPHORYLATION-0.140
- KRAS_SIGNALING_DN-0.130
- ALLOGRAFT_REJECTION-0.120
- UV_RESPONSE_UP-0.110
- INTERFERON_ALPHA_RESPONSE-0.070
- KRAS_SIGNALING_UP-0.070
- WNT_BETA_CATENIN_SIGNALING-0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | fec205e8-388c-47a2-9400-ec9fe2e0fab1 | — | — | 0.760 |
| 2 | MDT-AP-3249 | Med | Medulloblastoma | 0.723 |
| 3 | MNG56 | — | — | 0.715 |
| 4 | TCGA-D8-A1JJ-01A-31R-A14M-07 | — | C | 0.695 |
| 5 | ERR2278858 | — | — | 0.694 |
| 6 | TCGA-CQ-5326-01A-01R-1873-07 | — | — | 0.686 |
| 7 | MNG638 | — | — | 0.685 |
| 8 | TCGA-E9-A1RH-01A-21R-A169-07 | — | C | 0.681 |
| 9 | TCGA-77-7337-01A-21R-2045-07 | — | cohortSQ1 | 0.680 |
| 10 | TCGA-BL-A13J-01A-11R-A277-07 | — | — | 0.676 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 32 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.480 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.430 | Remibrutinib | — uncovered |
| G2M_CHECKPOINT | 0.410 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.390 | Remibrutinib | — uncovered |
| ANDROGEN_RESPONSE | 0.360 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.360 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.320 | Inavolisib | — uncovered |
| GLYCOLYSIS | 0.310 | Inavolisib | — uncovered |
| HYPOXIA | 0.300 | Idelalisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.290 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.280 | Remibrutinib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.270 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.250 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.220 | Temsirolimus | — uncovered |
| FATTY_ACID_METABOLISM | 0.210 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.210 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.200 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |